Wire flash
OpenAI acquires Orchestra Bio, a biopharma workflow platform
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
OpenAI announced that it has acquired Orchestra Bio, a platform designed to help biopharma teams coordinate the complex process of drug development. OpenAI said it will build on Rosalind, its AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. The company welcomed Ashok Raj and the Orchestra Bio team. The announcement links to OpenAI's website for further details.
Source report
OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development.
Together, we'll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner.
Welcome @ashokaraj_ and team!
For more information: openai.com/index/openai-to-acquire-orchestra-bio
Source
xNeutral / independent
Part of this Story
OpenAI Acquires Orchestra Bio to Add Drug-Development AI Agents to Rosalind